Patents by Inventor Adnan M. M. Mjalli

Adnan M. M. Mjalli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7776919
    Abstract: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, ?-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.
    Type: Grant
    Filed: January 24, 2008
    Date of Patent: August 17, 2010
    Assignee: TransTech Pharm, Inc.
    Inventors: Adnan M. M. Mjalli, Robert C. Andrews, Ramesh Gopalaswamy, Christopher L. Wysong
  • Publication number: 20100197677
    Abstract: The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, and wherein said methods of use include uses for the treatment and/or prevention of disorders and diseases, such as diabetes.
    Type: Application
    Filed: April 13, 2010
    Publication date: August 5, 2010
    Applicant: TRANSTECH PHARMA, INC.
    Inventors: Adnan M.M. Mjalli, Dharma Rao Polisetti, Thomas Scott Yokum, Kalpathy Santhosh, Mustafa Guzel, Christopher Behme, Stephen Thomas Davis
  • Publication number: 20100190808
    Abstract: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-alpha or by PDE4, including but not limited to rheumatoid arthritis.
    Type: Application
    Filed: January 23, 2009
    Publication date: July 29, 2010
    Applicant: HIGH POINT PHARMACEUTICALS, LLC.
    Inventors: Adnan M. M. Mjalli, Bapu Gaddam, Dharmo Rao, Matthew Kostura, Mustafa Guzel
  • Patent number: 7763726
    Abstract: The present invention relates to compounds and methods from the treatment of cancer. The invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising compounds that inhibit Aurora kinase, and methods for the treatment of cancer using the compounds of the presentation invention or pharmaceutical compositions comprising compounds of the present invention.
    Type: Grant
    Filed: February 9, 2007
    Date of Patent: July 27, 2010
    Assignee: TransTech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Brian S. Grella, Govindan Subramanian, Murty N. Arimilli, Ramesh Gopalaswamy, Robert C. Andrews, Stephen Davis, Xiaochuan Guo, Jeff Zhu
  • Publication number: 20100152170
    Abstract: The present invention relates to compounds and methods from the treatment of cancer. The invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising compounds that inhibit Aurora kinase, and methods for the treatment of cancer using the compounds of the presentation invention or pharmaceutical compositions comprising compounds of the present invention.
    Type: Application
    Filed: February 10, 2010
    Publication date: June 17, 2010
    Applicant: TransTech Pharma, Inc.
    Inventors: Adnan M.M. Mjalli, Brian S. Grella, Govindan Subramanian, Murty N. Arimilli, Ramesh Gopalaswamy, Robert C. Andrews, Stephen Davis, Xiaochuan Guo, Jeff Zhu
  • Patent number: 7737285
    Abstract: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, ?-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.
    Type: Grant
    Filed: May 3, 2007
    Date of Patent: June 15, 2010
    Assignee: TransTech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Robert C. Andrews, Ramesh Gopalaswamy, Anitha Hari, Kwasi A. Avor, Ghassan Qabaja, Xiao-Chuan Guo, Suparna Gupta, David R. Jones, Xin Chen
  • Patent number: 7727983
    Abstract: The present invention provides oxadiazoanthracene derivatives of the formula (I), wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, pharmaceutical compositions comprising oxadiazoanthracene derivatives, use of the oxadiazoanthracene derivatives for the preparation of pharmaceutical compositions, methods of use thereof for the treatment and/or prevention of disorders and diseases, such as diabetes, and intermediates useful for the preparation of oxadiazoanthracene derivatives of Formula (I).
    Type: Grant
    Filed: March 6, 2009
    Date of Patent: June 1, 2010
    Assignee: TransTech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Dharma Rao Polisetti, Thomas Scott Yokum, Kalpathy Santhosh, Mustafa Guzel, Christopher Behme, Stephen Thomas Davis
  • Patent number: 7723369
    Abstract: The present invention provides imidazole derivatives of Formula (I-IV), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I-IV), and their use in treating human or animal disorders. The compounds of the invention inhibit protein tyrosine phosphatase 1B and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes.
    Type: Grant
    Filed: January 30, 2007
    Date of Patent: May 25, 2010
    Assignee: TransTech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Dharma R. Polisetti, Govindan Subramanian, James C. Quada, Ravindra R. Yarragunta, Robert C. Andrews, Rongyuan Xie
  • Patent number: 7714013
    Abstract: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, ?-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.
    Type: Grant
    Filed: August 28, 2006
    Date of Patent: May 11, 2010
    Assignee: Transtech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Robert C. Andrews, Ramesh Gopalaswamy, Anitha Hari, Kwasi A. Avor, Ghassan Qabaja, Xiao-Chuan Guo, Suparna Gupta, David R. Jones, Xin Chen
  • Publication number: 20100113331
    Abstract: The present invention provides imidazole derivatives of Formula (I-IV), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I-IV), and their use in treating human or animal disorders. The compounds of the invention inhibit protein tyrosine phosphatase 1B and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes.
    Type: Application
    Filed: January 11, 2010
    Publication date: May 6, 2010
    Applicant: TRANSTECH PHARMA, INC.
    Inventors: ADNAN M. M. MJALLI, DHARMA R. POLISETTI, GOVINDAN SUBRAMANIAN, JAMES C. QUADA, RAVINDRA R. YARRAGUNTA, ROBERT C. ANDREWS, RONGYUAN XIE
  • Publication number: 20100056587
    Abstract: Substituted aminothiazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted aminothiazole, and methods of use in treating human or animal disorders. The compounds may be useful as inhibitors of action of AgRP on a melanocortin receptor and thus may be useful for the management, treatment, control, or the adjunct treatment of diseases which may be responsive to the modulation of melanocortin receptors including obesity-related disorders.
    Type: Application
    Filed: August 25, 2009
    Publication date: March 4, 2010
    Inventors: Adnan M. M. Mjalli, Bapu Gaddam, Robert C. Andrews, Samuel Victory, Suparna Gupta
  • Publication number: 20090326006
    Abstract: The present invention is directed to benzazole compounds that inhibit ?-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which BACE is involved.
    Type: Application
    Filed: March 14, 2006
    Publication date: December 31, 2009
    Inventors: Adnan M.M. Mjalli, David Jones, Devi Reddy Gohmmukkula, Guoxiang Huang, Jeff Zhu, Mohan Rao, Robert C. Andrews, Tan Ren
  • Publication number: 20090306063
    Abstract: The present invention provides oxadiazoanthracene derivatives of the formula (I), wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, pharmaceutical compositions comprising oxadiazoanthracene derivatives, use of the oxadiazoanthracene derivatives for the preparation of pharmaceutical compositions, methods of use thereof for the treatment and/or prevention of disorders and diseases, such as diabetes, and intermediates useful for the preparation of oxadiazoanthracene derivatives of Formula (I).
    Type: Application
    Filed: March 6, 2009
    Publication date: December 10, 2009
    Applicant: Trans Tech. Pharma. Inc.
    Inventors: Adnan M.M. Mjalli, Dharma Rao Polisetti, Thomas Scott Yokum, Kalpathy Santhosh, Mustafa Guzel, Christopher Behme, Stephen Thomas Davis
  • Publication number: 20090247536
    Abstract: Embodiments of the present invention provide bissulfonamide compounds that are agonists of GalR1. The present invention further provides compositions comprising bissulfonamide compounds that are agonists of GalR1, and methods of use of such compounds and compositions.
    Type: Application
    Filed: June 12, 2009
    Publication date: October 1, 2009
    Inventors: Adnan M.M. Mjalli, Bapu Gaddam, Mohan Rao, Muralidhar Bondlela, Ramesh Gopalaswamy, Robert C. Andrews, Stephen Davis, Suvi Simila, Tan Ren
  • Patent number: 7582673
    Abstract: Embodiments of the present invention provide bissulfonamide compounds that are agonists of GalR1. The present invention further provides compositions comprising bissulfonamide compounds that are agonists of GalR1, and methods of use of such compounds and compositions.
    Type: Grant
    Filed: October 20, 2005
    Date of Patent: September 1, 2009
    Assignee: High Point Pharmaceuticals, LLC
    Inventors: Adnan M. M. Mjalli, Bapu Gaddam, Mohan Rao, Muralidhar Bondlela, Ramesh Gopalaswamy, Robert C. Andrews, Stephen Davis, Suvi Simila, Tan Ren
  • Patent number: 7544699
    Abstract: This invention provides aryl and heteroaryl compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention may be antagonists, or partial antagonist of factor IX and/or factor XI and thus, may be useful for inhibiting the intrinsic pathway of blood coagulation. The compounds may be useful in a variety of applications including the management, treatment and/or control of diseases caused in part by the intrinsic clotting pathway.
    Type: Grant
    Filed: August 6, 2004
    Date of Patent: June 9, 2009
    Assignee: Transtech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Robert C. Andrews, Xiao-Chuan Guo, Daniel Peter Christen, Devi Reddy Gohimmukkula, Guoxiang Huang, Robert Rothlein, Sameer Tyagi, Tripura Yaramasu, Christopher Behme
  • Patent number: 7541373
    Abstract: This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
    Type: Grant
    Filed: March 1, 2006
    Date of Patent: June 2, 2009
    Assignee: Novo Nordisk A/S
    Inventors: Dharma Rao Polisetti, Janos Tibor Kodra, Jesper Lau, Paw Bloch, Mustafa Guzel, Kalpathy Chidambareswaran Santhosh, Adnan M. M. Mjalli, Robert Carl Andrews, Govindan Subramanian, Michael Ankersen, Per Vedso, Anthony Murray, Lone Jeppesen, Jesper Lau
  • Publication number: 20090124654
    Abstract: This invention provides aryl and heteroaryl compounds of formula (X). The compounds of the invention may be useful as antagonists, or partial antagonist of factor IX and/or factor XI and thus, may be used to inhibit the intrinsic pathway of blood coagulation. Formula (X) wherein R102 is selected from the group consisting of —C(O)OH, —C(O)OCH3, —C(O)O-t-butyl, —C(O)NH—OCH2-phenyl, C(O)NHOH, and —C(O)NHSO2CH3; and wherein R101, R103, R104 and Y are as defined herein.
    Type: Application
    Filed: February 23, 2006
    Publication date: May 14, 2009
    Inventors: Adnan M.M. Mjalli, Devi Reddy Gohimmukkula, Sameer Tyagi
  • Patent number: 7501538
    Abstract: This invention provides aryl and heteroaryl compounds of Formula (I) as described herein, and methods of their preparation. Also provided are pharmaceutical compositions made with the compounds of Formula (I) and methods for making such compositions. The compounds of Formula (I) may activate an erythropoietin receptor and thus, may be useful to induce red blood cell production. The compounds of Formula (I) and compositions including compounds of Formula (I) may be useful in a variety of applications including the management, treatment and/or control of diseases caused at least in part by deficient (or inefficient) EPO production relative to hemoglobin level.
    Type: Grant
    Filed: August 6, 2004
    Date of Patent: March 10, 2009
    Assignee: TransTech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Guoxiang Huang, Murty N. Arimilli, Thomas Scott Yokum, Jeff Jiqun Zhu, Muralidhar Bondlela
  • Publication number: 20090060925
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
    Type: Application
    Filed: August 3, 2005
    Publication date: March 5, 2009
    Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF
    Inventors: Adnan M.M. Mjalli, Ye Edward Tian, Jeffrey C. Webster, Robert Rothlein, David M. Stern, Ann Marie Schmidt, Shi Du Yan